NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the third quarter 2024. MiNK will host a conference call and webcast at 8:30 a.m. ET. "Our progress this quarter reflects MiNK's commitment to advancing effective and scalable therapies in cancer and immune-mediated diseases," said Jennifer Buell, PhD, Chief Executive Officer of MiNK Therapeutics. "We have continued to expand our iNKT ce

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID:

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK's iNK

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics ((MiNK, NASDAQ:INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases. Dr. Kadlec recently served as the U.S. Senate-confirmed Assistant

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics ((MiNK, NASDAQ:INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and Autonomous Therapeutics, Inc. (Autonomous), a leader developing first-in-class, disease-activated RNA medicines, announced a research collaboration aimed at effectively targeting and treating metastatic tumors. This collaboration will leverage Autonomous' precision encrypted RNA™ (encRNA) technology and MiNK's innovative iNKT cell therapies, MiNK-215 and agenT-797. The companies will evaluate these technologies in state-of-the-art metastatic solid tumor models. The goal

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR. Presentation Details Title: AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibi

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer, will participate in a fireside chat and investor one-on-ones at the upcoming H.C. Wainwright 26th Annual Global Investment Conference on September 9-11th. The fireside chat will take place at 7:00 a.m. ET on Monday, September 9th. To access this event, please register at https://journey.ct.events/view/ad5300ce-

Expanded Access to AgenT-797 in Severe ARDS Reinforces Clinical Efficacy; Data Highlighted at ATS 2024 Annual MeetingPhase 2 Study in 2L Gastric Cancer Advances; Early Clinical Data to be Presented at Upcoming Medical ConferencePhase 1 Study in GvHD on Track for Activation in 2Q 2024 NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the second quarter 2024. MiNK executives will host a conference ca

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 4

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced today that it has regained compliance with the Nasdaq Capital Market's market value of listed securities ("MVLS") requirement. On July 23, 2024, MiNK received notice from NASDAQ confirming that the Company has satisfied the MVLS requirement as set forth in Nasdaq Listing Rule 5550(b)(2). Accordingly, the Company now satisfies the MVLS requirement for continued listin

B. Riley Securities reiterated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $10.00 from $24.00 previously

B. Riley Securities initiated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $24.00

Robert W. Baird initiated coverage of MiNK Therapeutics with a rating of Outperform and set a new price target of $26.00

William Blair initiated coverage of MiNK Therapeutics with a rating of Outperform

Evercore ISI Group initiated coverage of MiNK Therapeutics with a rating of Outperform and set a new price target of $30.00

Baird initiated coverage of MiNK Therapeutics with a rating of Outperform and set a new price target of $26.00

SC 13G - MiNK Therapeutics, Inc. (0001840229) (Subject)

SC 13D - MiNK Therapeutics, Inc. (0001840229) (Subject)

SC 13D/A - MiNK Therapeutics, Inc. (0001840229) (Subject)

SC 13D/A - MiNK Therapeutics, Inc. (0001840229) (Subject)

SC 13G - MiNK Therapeutics, Inc. (0001840229) (Subject)

SC 13D - MiNK Therapeutics, Inc. (0001840229) (Subject)

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the third quarter 2024. MiNK will host a conference call and webcast at 8:30 a.m. ET. "Our progress this quarter reflects MiNK's commitment to advancing effective and scalable therapies in cancer and immune-mediated diseases," said Jennifer Buell, PhD, Chief Executive Officer of MiNK Therapeutics. "We have continued to expand our iNKT ce

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID:

Expanded Access to AgenT-797 in Severe ARDS Reinforces Clinical Efficacy; Data Highlighted at ATS 2024 Annual MeetingPhase 2 Study in 2L Gastric Cancer Advances; Early Clinical Data to be Presented at Upcoming Medical ConferencePhase 1 Study in GvHD on Track for Activation in 2Q 2024 NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the second quarter 2024. MiNK executives will host a conference ca

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 4

Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS)AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call a

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (U.S. – NY), (800) 715-9871 (U.S. & Canada)

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapiesPublished clinical data in Nature Communications and Oncogene demonstrating clinical activity of allo-iNKTs, agenT-797, in solid tumors and severe acute respiratory distress NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) --  MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (U.S. – NY), 800-715-9871 (U.S. &

MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.AgenT-797 demonstrates potential beyond cancer, with improved survival in severe respiratory distress. MiNK plans for expansion in autoimmune and inflammatory diseases.Conference Call on Thursday, November 9, 2023, at 8:30 a.m. ET. NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer a

agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists without lymphodepletion.Initiating phase 1/2 expansion studies in NSCLC and gastric cancer, with majority costs planned for external, non-dilutive grant funding.MiNK to present an update on the novel FAP-CAR-iNKT IND-enabling program at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural kill

Clinical changes showed a rapid decrease in inflammatory cytokines, including IL-18 following agenT-797 administration, consistent with the data observed in the Phase 1 trial of agenT-797 in COVID-19 ARDS. The patient was extubated on day 37 and discharged home from the hospital on day 60, weaned off hemodialysis and returned to normal activities of daily living (ADLs) within 6 months of dosing.

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $9 price target.

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the same period last year.

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. What Happened: On Monday, MiNK Therapeutics entered into a stock purchase agreement to sell securities in a private investment in public equity (PIPE) agreement. MiNK said it will sell 4.64 million shares at a price of $1.25 per share, representing a 25% premium to current prices. The expected total of $5.8 million in financing is earmarked for accelerating the clinical trials of MiNK-215, the company’s leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein in solid tumors. The company

Gainers Tevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INKT) stock increased by 31.09% to $1.18. The company's market cap stands at $40.9 million. Dynatronics (NASDAQ:DYNT) stock increased by 21.69% to $0.57. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out 2 days ago. Tarsus Pharmaceuticals (NASDAQ:TARS) shares moved upwards by 18.08% to $43.69. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q1 earnings report came out 3 days ago. CareCloud (NASDAQ:CCLD) shares

Gainers Etao International Co (NASDAQ:ETAO) stock moved upwards by 96.6% to $4.9 during Monday's regular session. The company's market cap stands at $25.0 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 48.63% to $3.27. The market value of their outstanding shares is at $8.2 million. Adlai Nortye (NASDAQ:ANL) stock rose 47.3% to $12.21. The market value of their outstanding shares is at $450.3 million. Onconetix (NASDAQ:ONCO) stock moved upwards by 26.56% to $0.21. The company's market cap stands at $4.6 million. MSP Recovery (NASDAQ:LIFW) stock rose 24.42% to $1.63. The market value of their outstanding shares is at $24.1 million. Outset Medical (NASDAQ:OM) shares moved upwa

MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the American Association for Cancer